<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns:z="http://www.zotero.org/namespaces/export#"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:link="http://purl.org/rss/1.0/modules/link/"
 xmlns:dcterms="http://purl.org/dc/terms/"
 xmlns:bib="http://purl.org/net/biblio#"
 xmlns:foaf="http://xmlns.com/foaf/0.1/"
 xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">
    <z:Attachment rdf:about="#item_1493">
        <z:itemType>attachment</z:itemType>
        <dc:title>Sheehan et al. - 1989 - Generation and characterization of hamster monoclo.pdf</dc:title>
        <link:type>application/pdf</link:type>
        <rdf:type rdf:resource="http://www.zotero.org/namespaces/export#Attachment"/>
        <z:itemType>attachment</z:itemType>
        <dc:title>Sheehan et al. - 1989 - Generation and characterization of hamster monoclo.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <z:Attachment rdf:about="#item_1509">
        <z:itemType>attachment</z:itemType>
        <dc:title>Xentria - Reprotoxicity White Paper.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://www.nejm.org/doi/10.1056/NEJMra2101555">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0028-4793,%201533-4406"/>
        <bib:editors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Longo</foaf:surname>
                        <foaf:givenName>Dan L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:editors>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Drent</foaf:surname>
                        <foaf:givenName>Marjolein</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Crouser</foaf:surname>
                        <foaf:givenName>Elliott D.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Grunewald</foaf:surname>
                        <foaf:givenName>Johan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1491"/>
        <dc:subject>Algorithms</dc:subject>
        <dc:subject>Biopsy</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Glucocorticoids</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Immunosuppressive Agents</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Prognosis</dc:subject>
        <dc:subject>Sarcoidosis</dc:subject>
        <dc:title>Challenges of Sarcoidosis and Its Management</dc:title>
        <dc:date>2021-09-09</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://www.nejm.org/doi/10.1056/NEJMra2101555</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:46</dcterms:dateSubmitted>
        <dc:description>PMID: 34496176</dc:description>
        <bib:pages>1018-1032</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0028-4793,%201533-4406">
        <prism:volume>385</prism:volume>
        <dc:title>New England Journal of Medicine</dc:title>
        <dc:identifier>DOI 10.1056/NEJMra2101555</dc:identifier>
        <prism:number>11</prism:number>
        <dcterms:alternative>N Engl J Med</dcterms:alternative>
        <dc:identifier>ISSN 0028-4793, 1533-4406</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1491">
        <z:itemType>attachment</z:itemType>
        <dc:title>Drent et al. - 2021 - Challenges of Sarcoidosis and Its Management.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://journals.aai.org/jimmunol/article/182/5/2583/81311/FcRn-in-the-Yolk-Sac-Endoderm-of-Mouse-Is-Required">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0022-1767,%201550-6606"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kim</foaf:surname>
                        <foaf:givenName>Jonghan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mohanty</foaf:surname>
                        <foaf:givenName>Sudhasri</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ganesan</foaf:surname>
                        <foaf:givenName>Latha P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hua</foaf:surname>
                        <foaf:givenName>Keding</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jarjoura</foaf:surname>
                        <foaf:givenName>David</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hayton</foaf:surname>
                        <foaf:givenName>William L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Robinson</foaf:surname>
                        <foaf:givenName>John M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Anderson</foaf:surname>
                        <foaf:givenName>Clark L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1492"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Endoderm</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Fetus</dc:subject>
        <dc:subject>Histocompatibility Antigens Class I</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Immunoglobulin G</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Maternal-Fetal Exchange</dc:subject>
        <dc:subject>Mice</dc:subject>
        <dc:subject>Mice, Inbred C57BL</dc:subject>
        <dc:subject>Mice, Knockout</dc:subject>
        <dc:subject>Mice, Transgenic</dc:subject>
        <dc:subject>Placenta</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Protein Transport</dc:subject>
        <dc:subject>Receptors, Fc</dc:subject>
        <dc:subject>Yolk Sac</dc:subject>
        <dc:title>FcRn in the Yolk Sac Endoderm of Mouse Is Required for IgG Transport to Fetus</dc:title>
        <dcterms:abstract>In adults the nonclassical MHC-I molecule, FcRn, binds both IgG and albumin and rescues both from a degradative fate, endowing both proteins with high plasma concentrations. FcRn also transports IgG from mother to young during gestation. Anticipating that a detailed understanding of gestational IgG transport in the mouse may give us a useful model to understand FcRn function in the human placenta, we have studied FcRn in the mouse yolk sac placenta in detail. Analyzing day 19-20 fetuses of the three FcRn genotypes resulting from matings of FcRn+/− parents, we found that FcRn−/− fetuses showed negligible IgG concentrations (1.5 μg/mL) whereas IgG concentrations in FcRn+/− fetuses were about a half (176 μg/mL) that of FcRn+/+ fetuses (336 μg/mL), indicating that FcRn is responsible for virtually all IgG transport from mother to fetus. Immunofluorescence and immunoblotting studies indicated that FcRn is expressed in the endoderm of the yolk sac placenta but not in other cells of the yolk sac placenta or in the chorioallantoic placenta. IgG was found in the endoderm of both FcRn+/+ and FcRn−/− yolk sac placentas and in the mesenchyme of FcRn+/+, but was missing from the mesenchyme of FcRn−/− yolk sac placentas, indicating that IgG enters the endoderm constitutively but is moved out of the endoderm by FcRn. The similarities of these results to human placental FcRn expression and function are striking.</dcterms:abstract>
        <dc:date>2009-03-01</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.aai.org/jimmunol/article/182/5/2583/81311/FcRn-in-the-Yolk-Sac-Endoderm-of-Mouse-Is-Required</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:48</dcterms:dateSubmitted>
        <dc:description>PMCID: PMC2676880
PMID: 19234152</dc:description>
        <bib:pages>2583-2589</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0022-1767,%201550-6606">
        <prism:volume>182</prism:volume>
        <dc:title>The Journal of Immunology</dc:title>
        <dc:identifier>DOI 10.4049/jimmunol.0803247</dc:identifier>
        <prism:number>5</prism:number>
        <dc:identifier>ISSN 0022-1767, 1550-6606</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1492">
        <z:itemType>attachment</z:itemType>
        <dc:title>Kim et al. - 2009 - FcRn in the Yolk Sac Endoderm of Mouse Is Required.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://journals.aai.org/jimmunol/article/142/11/3884/21261/Generation-and-characterization-of-hamster">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>142</prism:volume>
                <dc:title>The Journal of Immunology</dc:title>
                <dc:identifier>DOI 10.4049/jimmunol.142.11.3884</dc:identifier>
                <prism:number>11</prism:number>
                <dc:identifier>ISSN 0022-1767, 1550-6606</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sheehan</foaf:surname>
                        <foaf:givenName>K C</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ruddle</foaf:surname>
                        <foaf:givenName>N H</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schreiber</foaf:surname>
                        <foaf:givenName>R D</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1493"/>
        <dc:title>Generation and characterization of hamster monoclonal antibodies that neutralize murine tumor necrosis factors.</dc:title>
        <dcterms:abstract>Abstract
            mAb to murine TNF (MuTNF) were produced after immunization of Armenian hamsters with purified, Escherichia coli-derived rMuTNF-alpha. Antibody produced from clone TN3-19.12, was purified and was found to inhibit 100% of the lytic activity of either recombinant or natural MuTNF-alpha at an antibody input of 25 ng/U. TN3-19.12 also inhibited all the lytic activity in culture supernatants from a variety of T cell sources, including activated T cell clones and T cell hybridomas (all of which expressed high levels of TNF-alpha and TNF-beta (lymphotoxin, LT) mRNA). Western blot analysis was used to document the physical form(s) of MuTNF recognized by TN3-19.12. Recombinant and macrophage-derived TNF displayed identical patterns of a single band with Mr 17 kDa. In contrast, T cell culture supernatants exhibited patterns consisting of two bands with Mr 17 and 24.7 kDa. The higher m.w. form was glycosylated based on its sensitivity to n-glycanase and displayed a m.w. consistent with that of TNF-beta (LT). These data suggest that TN3-19.12 recognizes both MuTNF-alpha and MuTNF-beta (LT). Monoclonal TN3-19.12 and polyvalent rabbit anti-rTNF were used to establish a MuTNF-specific ELISA capable of detecting picogram quantities of recombinant or natural TNF. This assay was used to detect TNF in the sera of mice challenged with a lethal dose of LPS. Peak TNF serum levels of 11 ng/ml were observed in these animals 90 min after i.p. LPS administration and then rapidly declined to near base line levels by 3 h. These values were confirmed by quantitating levels of TNF functional activity in the same samples. TN3-19.12 injected into mice subsequently treated with LPS prevented the detection of TNF in the circulation by either assay and protected mice from the lethal effects of endotoxin shock. Thus, TN3-19.12 effectively neutralizes endogenously produced TNF in vivo.</dcterms:abstract>
        <dc:date>1989-06-01</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.aai.org/jimmunol/article/142/11/3884/21261/Generation-and-characterization-of-hamster</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:50</dcterms:dateSubmitted>
        <bib:pages>3884-3893</bib:pages>
    </bib:Article>
    <bib:Article rdf:about="https://www.frontiersin.org/articles/10.3389/fimmu.2020.545413/full">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1664-3224"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gerke</foaf:surname>
                        <foaf:givenName>Alicia K.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1494"/>
        <dc:title>Treatment of Sarcoidosis: A Multidisciplinary Approach</dc:title>
        <dcterms:abstract>Sarcoidosis is a systemic disease of unknown etiology deﬁned by the presence of noncaseating granulomatous inﬂammation that can cause organ damage and diminished quality of life. Treatment is indicated to protect organ function and decrease symptomatic burden. Current treatment options focus on interruption of granuloma formation and propagation. Clinical trials guiding evidence for treatment are lacking due to the rarity of disease, heterogeneous clinical course, and lack of prognostic biomarkers, all of which contribute to difﬁculty in clinical trial design and implementation. In this review, a multidisciplinary treatment approach is summarized, addressing immunuosuppressive drugs, managing complications of chronic granulomatous inﬂammation, and assessing treatment toxicity. Discovery of new therapies will depend on research into pathogenesis of antigen presentation and granulomatous inﬂammation. Future treatment approaches may also include personalized decisions based on pharmacogenomics and sarcoidosis phenotype, as well as patient-centered approaches to manage immunosuppression, symptom control, and treatment of comorbid conditions.</dcterms:abstract>
        <dc:date>2020-11-19</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>Treatment of Sarcoidosis</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.frontiersin.org/articles/10.3389/fimmu.2020.545413/full</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:52</dcterms:dateSubmitted>
        <dc:description>PMCID: PMC7732561
PMID: 33329511</dc:description>
        <bib:pages>545413</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1664-3224">
        <prism:volume>11</prism:volume>
        <dc:title>Frontiers in Immunology</dc:title>
        <dc:identifier>DOI 10.3389/fimmu.2020.545413</dc:identifier>
        <dcterms:alternative>Front. Immunol.</dcterms:alternative>
        <dc:identifier>ISSN 1664-3224</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1494">
        <z:itemType>attachment</z:itemType>
        <dc:title>Gerke - 2020 - Treatment of Sarcoidosis A Multidisciplinary Appr.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0021925820780385">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:00219258"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bossen</foaf:surname>
                        <foaf:givenName>Claudia</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ingold</foaf:surname>
                        <foaf:givenName>Karine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tardivel</foaf:surname>
                        <foaf:givenName>Aubry</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bodmer</foaf:surname>
                        <foaf:givenName>Jean-Luc</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Gaide</foaf:surname>
                        <foaf:givenName>Olivier</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hertig</foaf:surname>
                        <foaf:givenName>Sylvie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ambrose</foaf:surname>
                        <foaf:givenName>Christine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tschopp</foaf:surname>
                        <foaf:givenName>Jürg</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schneider</foaf:surname>
                        <foaf:givenName>Pascal</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1495"/>
        <dc:subject>Alternative Splicing</dc:subject>
        <dc:subject>Amino Acid Sequence</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Cell Membrane</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Ligands</dc:subject>
        <dc:subject>Mice</dc:subject>
        <dc:subject>Mice, Inbred C57BL</dc:subject>
        <dc:subject>Molecular Sequence Data</dc:subject>
        <dc:subject>Protein Binding</dc:subject>
        <dc:subject>Receptors, Tumor Necrosis Factor</dc:subject>
        <dc:subject>Sequence Homology, Amino Acid</dc:subject>
        <dc:subject>Species Specificity</dc:subject>
        <dc:subject>Tumor Necrosis Factors</dc:subject>
        <dc:title>Interactions of Tumor Necrosis Factor (TNF) and TNF Receptor Family Members in the Mouse and Human</dc:title>
        <dc:date>05/2006</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0021925820780385</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:54</dcterms:dateSubmitted>
        <dc:description>PMID: 16547002</dc:description>
        <bib:pages>13964-13971</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:00219258">
        <prism:volume>281</prism:volume>
        <dc:title>Journal of Biological Chemistry</dc:title>
        <dc:identifier>DOI 10.1074/jbc.M601553200</dc:identifier>
        <prism:number>20</prism:number>
        <dcterms:alternative>Journal of Biological Chemistry</dcterms:alternative>
        <dc:identifier>ISSN 00219258</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1495">
        <z:itemType>attachment</z:itemType>
        <dc:title>Bossen et al. - 2006 - Interactions of Tumor Necrosis Factor (TNF) and TN.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.2007.00499.x">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1046-7408,%201600-0897"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Martin</foaf:surname>
                        <foaf:givenName>Pauline L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Oneda</foaf:surname>
                        <foaf:givenName>Satoru</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Treacy</foaf:surname>
                        <foaf:givenName>George</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1496"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Antibodies, Monoclonal</dc:subject>
        <dc:subject>Embryonic Development</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Fetal Development</dc:subject>
        <dc:subject>Immune System</dc:subject>
        <dc:subject>Lactation</dc:subject>
        <dc:subject>Macaca fascicularis</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Tumor Necrosis Factor-alpha</dc:subject>
        <dc:title>Effects of an Anti-TNF-? Monoclonal Antibody, Administered Throughout Pregnancy and Lactation, on the Development of the Macaque Immune System</dc:title>
        <dcterms:abstract>Method of study Pregnant macaques were treated with golimumab during pregnancy and lactation. Immune system development was evaluated by histopathology, lymphocyte subset analysis and functional challenging of the infant immune system (humoral immune response to KLH and TTX, and DTH skin reaction).
Results In utero and postnatal exposure to golimumab had no effect on T and B cell populations in blood and lymphoid tissues and did not impair the ability of the infants to mount an immune response to antigen challenge.
Conclusion Treatment of pregnant macaques with golimumab throughout pregnancy and lactation did not affect the development and maturation of the immune system in the offspring.</dcterms:abstract>
        <dc:date>08/2007</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>Effects of an Anti-TNF-?</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.2007.00499.x</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:56</dcterms:dateSubmitted>
        <dc:description>PMID: 17631007</dc:description>
        <bib:pages>138-149</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1046-7408,%201600-0897">
        <prism:volume>58</prism:volume>
        <dc:title>American Journal of Reproductive Immunology</dc:title>
        <dc:identifier>DOI 10.1111/j.1600-0897.2007.00499.x</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Am J Reprod Immunol</dcterms:alternative>
        <dc:identifier>ISSN 1046-7408, 1600-0897</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1496">
        <z:itemType>attachment</z:itemType>
        <dc:title>Martin et al. - 2007 - Effects of an Anti-TNF- Monoclonal Antibody, Admi.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.frontiersin.org/articles/10.3389/fphys.2021.787369/full">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1664-042X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Araujo</foaf:surname>
                        <foaf:givenName>Gabriel Gomes</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>dos Passos Junior</foaf:surname>
                        <foaf:givenName>Rinaldo Rodrigues</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lunardi</foaf:surname>
                        <foaf:givenName>Rosaline Rocha</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Volpato</foaf:surname>
                        <foaf:givenName>Gustavo Tadeu</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Soares</foaf:surname>
                        <foaf:givenName>Thaigra Sousa</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Giachini</foaf:surname>
                        <foaf:givenName>Fernanda Regina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lima</foaf:surname>
                        <foaf:givenName>Victor Vitorino</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1497"/>
        <dc:subject>etanercept</dc:subject>
        <dc:subject>malformation</dc:subject>
        <dc:subject>medication</dc:subject>
        <dc:subject>placenta</dc:subject>
        <dc:subject>pregnancy</dc:subject>
        <dc:subject>TNF-α</dc:subject>
        <dc:title>Maternal and Fetal-Placental Effects of Etanercept Treatment During Rats’ Pregnancy</dc:title>
        <dcterms:abstract>Etanercept is a tumor necrosis factor alpha (TNF-α) inhibitor chronically used to treat autoimmune diseases. However, the use of etanercept during pregnancy still needs to be further investigated. The aim of this study is to evaluate the etanercept treatment during pregnancy, analyzing maternal reproductive performance, fetal outcomes, and placental repercussions. Wistar rats (200–250 g) were mated and randomly distributed into two experimental groups: control and etanercept (n = 10 animals/group). Treatments with etanercept (0.8 mg/kg, s.c.), or saline (control group) were carried out on days 0, 6, 12, and 18 of gestation. On the morning of the 21st day of pregnancy, rats were euthanized in a CO2 chamber and submitted to laparotomy to remove the fetuses, placentas, ovaries, and maternal organs. There were no differences between groups in the following parameters: water and food consumption; placental efﬁciency; reproductive parameters, including number of corpora lutea and implants, reabsorption, and pre- and post-implantation losses. However, etanercept treatment increased liver weight, reduced fetal and placental weight, decreased the placental junction zone, reduced the percentage of normal fetuses, and increased visceral or skeletal fetal abnormalities. Therefore, etanercept resulted in damages more related to fetus and placenta. However, more studies with different doses are required to better predict possible injuries elicited using etanercept during pregnancy.</dcterms:abstract>
        <dc:date>2022-2-3</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.frontiersin.org/articles/10.3389/fphys.2021.787369/full</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:02:58</dcterms:dateSubmitted>
        <dc:description>PMCID: PMC8851240
PMID: 35185598</dc:description>
        <bib:pages>787369</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1664-042X">
        <prism:volume>12</prism:volume>
        <dc:title>Frontiers in Physiology</dc:title>
        <dc:identifier>DOI 10.3389/fphys.2021.787369</dc:identifier>
        <dcterms:alternative>Front. Physiol.</dcterms:alternative>
        <dc:identifier>ISSN 1664-042X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1497">
        <z:itemType>attachment</z:itemType>
        <dc:title>Araujo et al. - 2022 - Maternal and Fetal-Placental Effects of Etanercept.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://link.springer.com/10.1007/BF00214978">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0302-766X,%201432-0878"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Dijkstra</foaf:surname>
                        <foaf:givenName>ChristineD.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>D�pp</foaf:surname>
                        <foaf:givenName>E.A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1498"/>
        <dc:title>Ontogenetic development of T- and B-lymphocytes and non-lymphoid cells in the white pulp of the rat spleen</dc:title>
        <dcterms:abstract>The location and temporal appearance of the different classes of lymphocytes were investigated in the developing white pulp of the rat spleen. Additionally, indications were sought for the involvement of non-lymphoid cells in the localization of lymphocytes. The lymphocytes were demonstrated by their surface determinants (W3/13, IgM, IgG, IgA, Ia) in a two-step immunoperoxidase method; the non-lymphoid cells were characterized by immuno-enzyme-histochemical techniques. The results showed that 1) already at birth strongly Ia-positive cells are present in the T-cell area; 2) the marginal zone develops as a distinct compartment, independent of the PALS and follicles; 3) follicles are recognizable at day 14, the capacity to trap immune complexes on follicular dendritic cells occurring one week later.</dcterms:abstract>
        <dc:date>2/1983</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>http://link.springer.com/10.1007/BF00214978</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:00</dcterms:dateSubmitted>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0302-766X,%201432-0878">
        <prism:volume>229</prism:volume>
        <dc:title>Cell and Tissue Research</dc:title>
        <dc:identifier>DOI 10.1007/BF00214978</dc:identifier>
        <prism:number>2</prism:number>
        <dcterms:alternative>Cell Tissue Res.</dcterms:alternative>
        <dc:identifier>ISSN 0302-766X, 1432-0878</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1498">
        <z:itemType>attachment</z:itemType>
        <dc:title>Dijkstra and D�pp - 1983 - Ontogenetic development of T- and B-lymphocytes an.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0264410X03003347">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0264410X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Simister</foaf:surname>
                        <foaf:givenName>N</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1499"/>
        <dc:title>Placental transport of immunoglobulin G</dc:title>
        <dcterms:abstract>Maternal antibodies transported across the placenta protect the newborn. Maternal immunoglobulin G (IgG) concentrations in fetal blood increase from early in the second trimester through term, most antibodies being acquired during the third trimester. IgG1 is the most efﬁciently transported subclass and IgG2 the least. Transfer across the syncytiotrophoblast of the chorionic villi is mediated by the neonatal Fc receptor, FcRn. Immune complexes are absorbed in the stroma of the villi, probably by Fc␥RI, Fc␥RII, and Fc␥RIII on placental macrophages. The mechanism of IgG transport across the endothelium of fetal capillaries is not understood. Endothelial cells in terminal villi express Fc␥RIIb. However, it is not known whether this receptor transports IgG or prevents transport of immune complexes to the fetus. © 2003 Elsevier Science Ltd. All rights reserved.</dcterms:abstract>
        <dc:date>2003-07-28</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0264410X03003347</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:02</dcterms:dateSubmitted>
        <bib:pages>3365-3369</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0264410X">
        <prism:volume>21</prism:volume>
        <dc:title>Vaccine</dc:title>
        <dc:identifier>DOI 10.1016/S0264-410X(03)00334-7</dc:identifier>
        <prism:number>24</prism:number>
        <dcterms:alternative>Vaccine</dcterms:alternative>
        <dc:identifier>ISSN 0264410X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1499">
        <z:itemType>attachment</z:itemType>
        <dc:title>Simister - 2003 - Placental transport of immunoglobulin G.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0002944010641016">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:00029440"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Qiu</foaf:surname>
                        <foaf:givenName>Boqin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Frait</foaf:surname>
                        <foaf:givenName>Kirsten A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Reich</foaf:surname>
                        <foaf:givenName>Filip</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Komuniecki</foaf:surname>
                        <foaf:givenName>Eric</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Chensue</foaf:surname>
                        <foaf:givenName>Stephen W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1500"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Antigens, Bacterial</dc:subject>
        <dc:subject>Antigens, Helminth</dc:subject>
        <dc:subject>Cell Division</dc:subject>
        <dc:subject>Cell Movement</dc:subject>
        <dc:subject>Chemokines</dc:subject>
        <dc:subject>Cytokines</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Granuloma</dc:subject>
        <dc:subject>Leukocytes</dc:subject>
        <dc:subject>Lung Diseases</dc:subject>
        <dc:subject>Mice</dc:subject>
        <dc:subject>Mice, Inbred CBA</dc:subject>
        <dc:subject>Mycobacterium</dc:subject>
        <dc:subject>RNA, Messenger</dc:subject>
        <dc:subject>Schistosoma mansoni</dc:subject>
        <dc:subject>Tuberculin</dc:subject>
        <dc:title>Chemokine Expression Dynamics in Mycobacterial (Type-1) and Schistosomal (Type-2) Antigen-Elicited Pulmonary Granuloma Formation</dc:title>
        <dc:date>04/2001</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0002944010641016</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:04</dcterms:dateSubmitted>
        <dc:description>PMID: 11290568
PMCID: PMC1891908</dc:description>
        <bib:pages>1503-1515</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:00029440">
        <prism:volume>158</prism:volume>
        <dc:title>The American Journal of Pathology</dc:title>
        <dc:identifier>DOI 10.1016/S0002-9440(10)64101-6</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>The American Journal of Pathology</dcterms:alternative>
        <dc:identifier>ISSN 00029440</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1500">
        <z:itemType>attachment</z:itemType>
        <dc:title>Qiu et al. - 2001 - Chemokine Expression Dynamics in Mycobacterial (Ty.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.frontiersin.org/article/10.3389/fendo.2018.00570/full">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1664-2392"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Woods</foaf:surname>
                        <foaf:givenName>Laura</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Perez-Garcia</foaf:surname>
                        <foaf:givenName>Vicente</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hemberger</foaf:surname>
                        <foaf:givenName>Myriam</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1501"/>
        <dc:subject>DMDD</dc:subject>
        <dc:subject>fetal growth restriction</dc:subject>
        <dc:subject>IUGR</dc:subject>
        <dc:subject>mouse models</dc:subject>
        <dc:subject>placenta</dc:subject>
        <dc:subject>trophoblast</dc:subject>
        <dc:title>Regulation of Placental Development and Its Impact on Fetal Growth—New Insights From Mouse Models</dc:title>
        <dcterms:abstract>The placenta is the chief regulator of nutrient supply to the growing embryo during gestation. As such, adequate placental function is instrumental for developmental progression throughout intrauterine development. One of the most common complications during pregnancy is insufﬁcient growth of the fetus, a problem termed intrauterine growth restriction (IUGR) that is most frequently rooted in a malfunctional placenta. Together with conventional gene targeting approaches, recent advances in screening mouse mutants for placental defects, combined with the ability to rapidly induce mutations in vitro and in vivo by CRISPR-Cas9 technology, has provided new insights into the contribution of the genome to normal placental development. Most importantly, these data have demonstrated that far more genes are required for normal placentation than previously appreciated. Here, we provide a summary of common types of placental defects in established mouse mutants, which will help us gain a better understanding of the genes impacting on human placentation. Based on a recent mouse mutant screen, we then provide examples on how these data can be mined to identify novel molecular hubs that may be critical for placental development. Given the close association between placental defects and abnormal cardiovascular and brain development, these functional nodes may also shed light onto the etiology of birth defects that co-occur with placental malformations. Taken together, recent insights into the regulation of mouse placental development have opened up new avenues for research that will promote the study of human pregnancy conditions, notably those based on defects in placentation that underlie the most common pregnancy pathologies such as IUGR and pre-eclampsia.</dcterms:abstract>
        <dc:date>2018-9-27</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.frontiersin.org/article/10.3389/fendo.2018.00570/full</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:06</dcterms:dateSubmitted>
        <dc:description>PMID: 30319550
PMCID: PMC6170611</dc:description>
        <bib:pages>570</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1664-2392">
        <prism:volume>9</prism:volume>
        <dc:title>Frontiers in Endocrinology</dc:title>
        <dc:identifier>DOI 10.3389/fendo.2018.00570</dc:identifier>
        <dcterms:alternative>Front. Endocrinol.</dcterms:alternative>
        <dc:identifier>ISSN 1664-2392</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1501">
        <z:itemType>attachment</z:itemType>
        <dc:title>Woods et al. - 2018 - Regulation of Placental Development and Its Impact.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.mdpi.com/2075-4418/11/6/1089">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2075-4418"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Saketkoo</foaf:surname>
                        <foaf:givenName>Lesley Ann</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Russell</foaf:surname>
                        <foaf:givenName>Anne-Marie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Jensen</foaf:surname>
                        <foaf:givenName>Kelly</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mandizha</foaf:surname>
                        <foaf:givenName>Jessica</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tavee</foaf:surname>
                        <foaf:givenName>Jinny</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Newton</foaf:surname>
                        <foaf:givenName>Jacqui</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rivera</foaf:surname>
                        <foaf:givenName>Frank</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Howie</foaf:surname>
                        <foaf:givenName>Mike</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Reese</foaf:surname>
                        <foaf:givenName>Rodney</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Goodman</foaf:surname>
                        <foaf:givenName>Melanie</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hart</foaf:surname>
                        <foaf:givenName>Patricia</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Strookappe</foaf:surname>
                        <foaf:givenName>Bert</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>De Vries</foaf:surname>
                        <foaf:givenName>Jolanda</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rosenbach</foaf:surname>
                        <foaf:givenName>Misha</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Scholand</foaf:surname>
                        <foaf:givenName>Mary Beth</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lammi</foaf:surname>
                        <foaf:givenName>Mathew R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Elfferich</foaf:surname>
                        <foaf:givenName>Marjon</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lower</foaf:surname>
                        <foaf:givenName>Elyse</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Baughman</foaf:surname>
                        <foaf:givenName>Robert P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sweiss</foaf:surname>
                        <foaf:givenName>Nadera</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Judson</foaf:surname>
                        <foaf:givenName>Marc A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Drent</foaf:surname>
                        <foaf:givenName>Marjolein</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1502"/>
        <dc:subject>exercise</dc:subject>
        <dc:subject>mindfulness</dc:subject>
        <dc:subject>patient centered care</dc:subject>
        <dc:subject>patient-centeredness</dc:subject>
        <dc:subject>physical activity</dc:subject>
        <dc:subject>quality of life</dc:subject>
        <dc:subject>sarcoidosis</dc:subject>
        <dc:subject>shared decision making</dc:subject>
        <dc:subject>symptom burden</dc:subject>
        <dc:subject>symptom distress</dc:subject>
        <dc:title>Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes</dc:title>
        <dcterms:abstract>Health-related quality of life (HRQoL), though rarely considered as a primary endpoint in clinical trials, may be the single outcome reflective of patient priorities when living with a health condition. HRQoL is a multi-dimensional concept that reflects the degree to which a health condition interferes with participation in and fulfillment of important life areas. HRQoL is intended to capture the composite degree of physical, physiologic, psychological, and social impairment resulting from symptom burden, patient-perceived disease severity, and treatment side effects. Diminished HRQoL expectedly correlates to worsening disability and death; but interventions addressing HRQoL are linked to increased survival. Sarcoidosis, being a multi-organ system disease, is associated with a diffuse array of manifestations resulting in multiple symptoms, complications, and medication-related side effects that are linked to reduced HRQoL. Diminished HRQoL in sarcoidosis is related to decreased physical function, pain, significant loss of income, absence from work, and strain on personal relationships. Symptom distress can result clearly from a sarcoidosis manifestation (e.g., ocular pain, breathlessness, cough) but may also be non-specific, such as pain or fatigue. More complex, a single non-specific symptom, e.g., fatigue may be directly sarcoidosis-derived (e.g., inflammatory state, neurologic, hormonal, cardiopulmonary), medication-related (e.g., anemia, sleeplessness, weight gain, sub-clinical infection), or an indirect complication (e.g., sleep apnea, physical deconditioning, depression). Identifying and distinguishing underlying causes of impaired HRQoL provides opportunity for treatment strategies that can greatly impact a patient’s function, well-being, and disease outcomes. Herein, we present a reference manual that describes the current state of knowledge in sarcoidosis-related HRQoL and distinguish between diverse causes of symptom distress and other influences on sarcoidosis-related HRQoL. We provide tools to assess, investigate, and diagnose compromised HRQoL and its influencers. Strategies to address modifiable HRQoL factors through palliation of symptoms and methods to improve the sarcoidosis health profile are outlined; as well as a proposed research agenda in sarcoidosis-related HRQoL.</dcterms:abstract>
        <dc:date>2021-06-15</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>Health-Related Quality of Life (HRQoL) in Sarcoidosis</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
               <rdf:value>https://www.mdpi.com/2075-4418/11/6/1089</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:08</dcterms:dateSubmitted>
        <dc:description>PMID: 34203584
PMCID: PMC8232334</dc:description>
        <bib:pages>1089</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2075-4418">
        <prism:volume>11</prism:volume>
        <dc:title>Diagnostics</dc:title>
        <dc:identifier>DOI 10.3390/diagnostics11061089</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Diagnostics</dcterms:alternative>
        <dc:identifier>ISSN 2075-4418</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1502">
        <z:itemType>attachment</z:itemType>
        <dc:title>Saketkoo et al. - 2021 - Health-Related Quality of Life (HRQoL) in Sarcoido.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0022347681809791">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:00223476"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Shapiro</foaf:surname>
                        <foaf:givenName>R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Beatty</foaf:surname>
                        <foaf:givenName>D.W.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Woods</foaf:surname>
                        <foaf:givenName>D.L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Malan</foaf:surname>
                        <foaf:givenName>A.F.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Med</foaf:surname>
                        <foaf:givenName>M.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1503"/>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Blood Proteins</dc:subject>
        <dc:subject>Complement C3</dc:subject>
        <dc:subject>Complement C4</dc:subject>
        <dc:subject>Complement Pathway, Alternative</dc:subject>
        <dc:subject>Complement Pathway, Classical</dc:subject>
        <dc:subject>Complement System Proteins</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Immunodiffusion</dc:subject>
        <dc:subject>Immunoglobulin G</dc:subject>
        <dc:subject>Immunoglobulin M</dc:subject>
        <dc:subject>Immunoglobulins</dc:subject>
        <dc:subject>Infant, Newborn</dc:subject>
        <dc:subject>Infant, Small for Gestational Age</dc:subject>
        <dc:subject>Serum Globulins</dc:subject>
        <dc:title>Serum complement and immunoglobulin values in small-for-gestational-age infants</dc:title>
        <dc:date>7/1981</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0022347681809791</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:10</dcterms:dateSubmitted>
        <dc:description>PMID: 6788919</dc:description>
        <bib:pages>139-141</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:00223476">
        <prism:volume>99</prism:volume>
        <dc:title>The Journal of Pediatrics</dc:title>
        <dc:identifier>DOI 10.1016/S0022-3476(81)80979-1</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>The Journal of Pediatrics</dcterms:alternative>
        <dc:identifier>ISSN 00223476</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1503">
        <z:itemType>attachment</z:itemType>
        <dc:title>Shapiro et al. - 1981 - Serum complement and immunoglobulin values in smal.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S0022347609011214">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>156</prism:volume>
                <dc:title>The Journal of Pediatrics</dc:title>
                <dc:identifier>DOI 10.1016/j.jpeds.2009.11.014</dc:identifier>
                <prism:number>2</prism:number>
                <dcterms:alternative>The Journal of Pediatrics</dcterms:alternative>
                <dc:identifier>ISSN 00223476</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Brandtzaeg</foaf:surname>
                        <foaf:givenName>Per</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1504"/>
        <dc:title>The Mucosal Immune System and Its Integration with the Mammary Glands</dc:title>
        <dc:date>2/2010</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S0022347609011214</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:12</dcterms:dateSubmitted>
        <bib:pages>S8-S15</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_1504">
        <z:itemType>attachment</z:itemType>
        <dc:title>Brandtzaeg - 2010 - The Mucosal Immune System and Its Integration with.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S1472648312002076">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:14726483"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lefebvre</foaf:surname>
                        <foaf:givenName>Louis</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1505"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Basic Helix-Loop-Helix Transcription Factors</dc:subject>
        <dc:subject>Cell Lineage</dc:subject>
        <dc:subject>Cyclin-Dependent Kinase Inhibitor p57</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Gene Expression Regulation, Developmental</dc:subject>
        <dc:subject>Genomic Imprinting</dc:subject>
        <dc:subject>Glycogen</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Insulin-Like Growth Factor II</dc:subject>
        <dc:subject>Mice</dc:subject>
        <dc:subject>Mothers</dc:subject>
        <dc:subject>Nuclear Proteins</dc:subject>
        <dc:subject>Placenta</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Proteome</dc:subject>
        <dc:subject>Trophoblasts</dc:subject>
        <dc:title>The placental imprintome and imprinted gene function in the trophoblast glycogen cell lineage</dc:title>
        <dcterms:abstract>Imprinted genes represent a unique class of autosomal genes expressed from only one of the parental alleles during development. The choice of the expressed allele is not random but rather is determined by the parental origin of the allele. Consequently, the mouse genome contains more than one hundred genes expressed preferentially or exclusively from the maternally or the paternally inherited allele. Current research efforts are focused on understanding the molecular mechanism of this epigenetic phenomenon as well as the biological functions of the genes under its regulation. Both theoretical considerations and experimental results support a role for genomic imprinting in the regulation of embryonic growth and placental biology. In this review, recent effort to establish the complete set of genes showing imprinted expression in the mouse placenta are first discussed. Then, the evidence suggesting that imprinted genes might be implicated in the emergence, maintenance and function of trophoblast glycogen cells is presented. Although the origin and function of this trophoblast cell lineage are currently unknown, the analysis of mutations in imprinted genes in the mouse are providing new insights into these issues. The implications of this work for placental pathologies in human are also discussed.</dcterms:abstract>
        <dc:date>7/2012</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S1472648312002076</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:13</dcterms:dateSubmitted>
        <dc:description>PMCID: PMC3819294
PMID: 22560119</dc:description>
        <bib:pages>44-57</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:14726483">
        <prism:volume>25</prism:volume>
        <dc:title>Reproductive BioMedicine Online</dc:title>
        <dc:identifier>DOI 10.1016/j.rbmo.2012.03.019</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Reproductive BioMedicine Online</dcterms:alternative>
        <dc:identifier>ISSN 14726483</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1505">
        <z:itemType>attachment</z:itemType>
        <dc:title>Lefebvre - 2012 - The placental imprintome and imprinted gene functi.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://academic.oup.com/toxsci/article/1671712/The">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1096-6080,%201096-0929"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wakefield</foaf:surname>
                        <foaf:givenName>Ian</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Stephens</foaf:surname>
                        <foaf:givenName>Sue</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Foulkes</foaf:surname>
                        <foaf:givenName>Roly</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nesbitt</foaf:surname>
                        <foaf:givenName>Andrew</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bourne</foaf:surname>
                        <foaf:givenName>Tim</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1506"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Antibodies, Monoclonal, Humanized</dc:subject>
        <dc:subject>Certolizumab Pegol</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Immunoglobulin Fab Fragments</dc:subject>
        <dc:subject>Immunoglobulin G</dc:subject>
        <dc:subject>Male</dc:subject>
        <dc:subject>Polyethylene Glycols</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Rats</dc:subject>
        <dc:subject>Rats, Sprague-Dawley</dc:subject>
        <dc:subject>Tumor Necrosis Factor-alpha</dc:subject>
        <dc:title>The Use of Surrogate Antibodies to Evaluate the Developmental and Reproductive Toxicity Potential of an Anti-TNFα PEGylated Fab′ Monoclonal Antibody</dc:title>
        <dc:date>07/2011</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://academic.oup.com/toxsci/article/1671712/The</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:16</dcterms:dateSubmitted>
        <dc:description>PMID: 21507990</dc:description>
        <bib:pages>170-176</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1096-6080,%201096-0929">
        <prism:volume>122</prism:volume>
        <dc:title>Toxicological Sciences</dc:title>
        <dc:identifier>DOI 10.1093/toxsci/kfr083</dc:identifier>
        <prism:number>1</prism:number>
        <dc:identifier>ISSN 1096-6080, 1096-0929</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1506">
        <z:itemType>attachment</z:itemType>
        <dc:title>Wakefield et al. - 2011 - The Use of Surrogate Antibodies to Evaluate the De.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://journals.lww.com/00006250-200510000-00022">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0029-7844"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Aaltonen</foaf:surname>
                        <foaf:givenName>Riikka</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Heikkinen</foaf:surname>
                        <foaf:givenName>Tuija</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Hakala</foaf:surname>
                        <foaf:givenName>Kristo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Laine</foaf:surname>
                        <foaf:givenName>Kari</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Alanen</foaf:surname>
                        <foaf:givenName>Anna</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1507"/>
        <dc:subject>Adult</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Interleukin-1</dc:subject>
        <dc:subject>Interleukin-6</dc:subject>
        <dc:subject>Maternal-Fetal Exchange</dc:subject>
        <dc:subject>Middle Aged</dc:subject>
        <dc:subject>Organ Culture Techniques</dc:subject>
        <dc:subject>Placenta</dc:subject>
        <dc:subject>Placental Circulation</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Tumor Necrosis Factor-alpha</dc:subject>
        <dc:title>Transfer of Proinflammatory Cytokines Across Term Placenta:</dc:title>
        <dcterms:abstract>OBJECTIVE: Increased concentrations of proinflammatory cytokines in amniotic fluid indicate the presence of intraamniotic inflammation and increase the risk of preterm birth, cerebral palsy, and bronchopulmonary dysplasia. The purpose of this study was to find out if the proinflammatory cytokines, tumor necrosis factor alpha (TNF-␣), interleukin (IL)-1␤, and IL-6, transfer across the placenta, and thereby determine whether intra-amniotic inflammatory response, measured from the amniotic fluid, is of maternal or fetal origin.
METHODS: Nineteen placentas from healthy women undergoing elective cesarean delivery at term with intact membranes and without labor, were dually perfused ex vivo in an open circulation system for either 30 minutes or 2 hours. Tumor necrosis factor-␣, IL-1␤, and IL-6 were added to maternal or fetal circulation in a concentration usually found in chorioamnionitis. As a reference, placentas without added cytokine were also perfused. The concentrations of cytokines were determined by enzyme immunoassays (enzyme-linked immunosorbent assay [ELISA]).
RESULTS: After the addition of the cytokine to the arterial perfusate, the venous concentration on the same side of the placenta increased rapidly and reached a plateau at 10 minutes. No transfer of any cytokine in either direction was detected. Some endogenous release of IL-6 was observed in response to the perfusion.
CONCLUSION: Proinflammatory cytokines do not cross normal term placenta. (Obstet Gynecol 2005;106:802–7) LEVEL OF EVIDENCE: II-1</dcterms:abstract>
        <dc:date>10/2005</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>Transfer of Proinflammatory Cytokines Across Term Placenta</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://journals.lww.com/00006250-200510000-00022</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:18</dcterms:dateSubmitted>
        <dc:description>PMID: 16199639</dc:description>
        <bib:pages>802-807</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0029-7844">
        <prism:volume>106</prism:volume>
        <dc:title>Obstetrics &amp; Gynecology</dc:title>
        <dc:identifier>DOI 10.1097/01.AOG.0000178750.84837.ed</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Obstetrics &amp; Gynecology</dcterms:alternative>
        <dc:identifier>ISSN 0029-7844</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1507">
        <z:itemType>attachment</z:itemType>
        <dc:title>Aaltonen et al. - 2005 - Transfer of Proinflammatory Cytokines Across Term .pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://linkinghub.elsevier.com/retrieve/pii/S2542454819300499">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:25424548"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ungprasert</foaf:surname>
                        <foaf:givenName>Patompong</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ryu</foaf:surname>
                        <foaf:givenName>Jay H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Matteson</foaf:surname>
                        <foaf:givenName>Eric L.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1508"/>
        <dc:subject>ATS, American Thoracic Society</dc:subject>
        <dc:subject>AV, atrioventricular</dc:subject>
        <dc:subject>CMRI, cardiovascular magnetic resonance imaging</dc:subject>
        <dc:subject>DLCO, diffusing capacity of the lung for carbon monoxide</dc:subject>
        <dc:subject>DMARD, disease-modifying antirheumatic drugs</dc:subject>
        <dc:subject>ECG, electrocardiographic</dc:subject>
        <dc:subject>ERS, European Respiratory Society</dc:subject>
        <dc:subject>FDG-PET, 18F-fluorodeoxyglucose–positron emission tomography</dc:subject>
        <dc:subject>FVC, forced vital capacity</dc:subject>
        <dc:subject>GI, gastrointestinal tract</dc:subject>
        <dc:subject>LVEF, left ventricular ejection fraction</dc:subject>
        <dc:subject>NSAID, nonsteroidal anti-inflammatory drug</dc:subject>
        <dc:subject>PFT, pulmonary function test</dc:subject>
        <dc:subject>TBB, transbronchial lung biopsy</dc:subject>
        <dc:subject>TNF-α, tumor necrosis factor α</dc:subject>
        <dc:subject>WASOG, World Association of Sarcoidosis and other Granulomatous Disorders</dc:subject>
        <dc:title>Clinical Manifestations, Diagnosis, and Treatment of Sarcoidosis</dc:title>
        <dcterms:abstract>The focus of this review is current knowledge about the epidemiology, clinical manifestations, diagnosis, and treatment of both pulmonary sarcoidosis and extrapulmonary sarcoidosis. Although intrathoracic involvement is the hallmark of the disease, present in over 90% of patients, sarcoidosis can affect virtually any organ. Clinical presentations of sarcoidosis are diverse, ranging from asymptomatic, incidental ﬁndings to organ failure. Diagnosis requires the presence of noncaseating granuloma and compatible presentations after exclusion of other identiﬁable causes. Spontaneous remission is frequent, so treatment is not always indicated unless the disease is symptomatic or causes progressive organ damage/dysfunction. Glucocorticoids are the cornerstone of treatment of sarcoidosis even though evidence from randomized controlled studies is lacking. Glucocorticoid-sparing agents and biologic agents are often used as secondand third-line therapy for patients who do not respond to glucocorticoids or experience serious adverse effects.</dcterms:abstract>
        <dc:date>09/2019</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://linkinghub.elsevier.com/retrieve/pii/S2542454819300499</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:20</dcterms:dateSubmitted>
        <dc:description>PMID: 31485575
PMCID: PMC6713839</dc:description>
        <bib:pages>358-375</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:25424548">
        <prism:volume>3</prism:volume>
        <dc:title>Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes</dc:title>
        <dc:identifier>DOI 10.1016/j.mayocpiqo.2019.04.006</dc:identifier>
        <prism:number>3</prism:number>
        <dcterms:alternative>Mayo Clinic Proceedings: Innovations, Quality &amp; Outcomes</dcterms:alternative>
        <dc:identifier>ISSN 25424548</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1508">
        <z:itemType>attachment</z:itemType>
        <dc:title>Ungprasert et al. - 2019 - Clinical Manifestations, Diagnosis, and Treatment .pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.1996.tb00172.x">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:10467408"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Malek</foaf:surname>
                        <foaf:givenName>Antoine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sager</foaf:surname>
                        <foaf:givenName>Ruth</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Kuhn</foaf:surname>
                        <foaf:givenName>Peter</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nicolaides</foaf:surname>
                        <foaf:givenName>Kypros H.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schneider</foaf:surname>
                        <foaf:givenName>Henning</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1510"/>
        <dc:title>Evolution of Maternofetal Transport of Immunoglobulins During Human Pregnancy</dc:title>
        <dcterms:abstract>METHOD: Paired blood samples were collected between 17-41 weeks of gestation (WG) by puncture of a peripheral maternal vein and by cordocentesis (17-36 WG, n=91) or directly at delivery (37-41 WG, n=16) from the umbilical vein. Additional maternal samples were collected from the same individual (n=16) at 10,20,30 WG, and at term. The concentration of IgG and its four subclasses and of IgA were determined in the sera using ELISA method.
RESULTS: The mean level of IgG and IgA in maternal sera at 9-16 WG was 13.72f2.53 g/L and 3.95f1.23 g/L, respectively. Both, IgG and IgA throughout pregnancy decreased to a level of 6 6 7 0 % (37-41 WG) of the initial concentration in early pregnancy. The ratio of IgGl:IgG2 in the maternal circulation was 2-3 and remained constant throughout pregnancy (17-41 WG). IgG3 and IgG4 levels remained constant and together were less than 10 % of total IgG. In the fetal circulation a continuous rise in the level of both IgG and IgA was observed between 17 and 41 WG. Fetal level of IgG at 17-22 WG was only 5-10% of the maternal level and at term exceeded the maternal level reaching a value of 11.98f2.18 g/L. IgGl at 17-22 WG was 0.93f0.42 g/L, which is approximately three times higher than IgG2. IgGl showed an exponential rise and at 37-41 WG its concentration was seven times higher than IgG2. IgG3 and IgG4 also showed an exponential rise and at term reached a similar level as in the maternal circulation, Striking was the difference in results for IgG2 with a slow linear rise throughout gestation. The fetal IgG2 level at term remained significantly below the maternal concentration. The IgG subclasses when characterized according to the differences in transport capacity gave the following sequence: IgGpIgG4&gt;IgG3&gt;IgG2. Fetal IgA showed a slow linear rise with fetal levels at term remaining approximately 1,000 times lower than the concentration in the maternal circulation.
CONCLUSIONS: Comparison of fetal and maternal levels of immunglobulines indicate that the human placenta during pregnancy develops a specific transport mechanism for IgG. There are differences for the four subclasses with preferential transfer of IgGl while the slowest transfer is seen for IgG2.</dcterms:abstract>
        <dc:date>11/1996</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.1996.tb00172.x</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:22</dcterms:dateSubmitted>
        <bib:pages>248-255</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:10467408">
        <prism:volume>36</prism:volume>
        <dc:title>American Journal of Reproductive Immunology</dc:title>
        <dc:identifier>DOI 10.1111/j.1600-0897.1996.tb00172.x</dc:identifier>
        <prism:number>5</prism:number>
        <dc:identifier>ISSN 10467408</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1510">
        <z:itemType>attachment</z:itemType>
        <dc:title>Malek et al. - 1996 - Evolution of Maternofetal Transport of Immunoglobu.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.1994.tb00873.x">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf>
            <bib:Journal>
                <prism:volume>32</prism:volume>
                <dc:title>American Journal of Reproductive Immunology</dc:title>
                <dc:identifier>DOI 10.1111/j.1600-0897.1994.tb00873.x</dc:identifier>
                <prism:number>1</prism:number>
                <dc:identifier>ISSN 10467408</dc:identifier>
            </bib:Journal>
        </dcterms:isPartOf>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Malek</foaf:surname>
                        <foaf:givenName>Antoine</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Sager</foaf:surname>
                        <foaf:givenName>Ruth</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Schneider</foaf:surname>
                        <foaf:givenName>Henning</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1511"/>
        <dc:subject>Enzyme-Linked Immunosorbent Assay</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Fetal Blood</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Immunoglobulin G</dc:subject>
        <dc:subject>Infant, Newborn</dc:subject>
        <dc:subject>Maternal-Fetal Exchange</dc:subject>
        <dc:subject>Pregnancy</dc:subject>
        <dc:subject>Pregnancy Trimester, Third</dc:subject>
        <dc:subject>Umbilical Arteries</dc:subject>
        <dc:subject>Umbilical Veins</dc:subject>
        <dc:title>Maternal-Fetal Transport of Immunoglobulin G and Its Subclasses During the Third Trimester of Human Pregnancy</dc:title>
        <dcterms:abstract>METHOD: The concentration of IgG and its subclasses (IgG I-4 ) was determined in sera of blood samples from 38 pregnancies collected at the time of delivery from a peripheral maternal vein (MV) and from the placental umbilical artery (UA) and vein (UV). Gestational age varied between 28 and 42 weeks (WG).
RESULT: Whereas placental weight showed a significant correlation with gestational age, the maternal level of IgG and the ratio of its subclasses did not vary with gestational age. At 28-33 WG (n = 15) the mean values in the UA (5.91 ± 1.53 g/l) and UV (6.41 ± 1.57 g/l) for total IgG concentration were lower than in the MV (10.74 ± 2.55 g/l). At the end of gestation (37--42 WG, n = 12), IgG in both UA (11.21 ± 1.95 g/l) and UV (12.26 ± 2.06 g/l) exceeded the maternal concentration (9.69 ± 1.84 g/l). In addition to the significant positive correlation between IgG concentration in the fetal circulation (UV + UA) and gestational age (28--42 WG), an increase in the positive difference between UV and UA at the end of pregnancy indicates that there is a substantial rise in placental IgG transport capacity.
CONCLUSION: All four subclasses IgG I-4 were detectable in the umbilical circulation (28--42 WG). Whereas IgG 3 and IgG 4 in UA and UV had a similar concentration as in MV and remained unchanged, IgG z increased with gestation from 0.67/0.74 gil (UA/UV, 28-33 WG) to 1.29/1.58 gil (UA/UV, 37--42 WG), but nevertheless remained lower than the level found in the MV (2.65 ± 1.12 gil). The main increase in IgG concentration, however, was due to the substantial rise in the transport of IgG&quot; which increased from 4.37 ± 1.24 (UA) and 4.94 ± 1.52 gil (UV) at 28-33 WG to 8.94 ± 1.66 (UA) and 10.89 ± 1.96 gil (UV) at the end of gestation, which was even higher than the overall IgG concentration in MY.</dcterms:abstract>
        <dc:date>08/1994</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://onlinelibrary.wiley.com/doi/10.1111/j.1600-0897.1994.tb00873.x</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:25</dcterms:dateSubmitted>
        <dc:description>PMID: 7945815</dc:description>
        <bib:pages>8-14</bib:pages>
    </bib:Article>
    <z:Attachment rdf:about="#item_1511">
        <z:itemType>attachment</z:itemType>
        <dc:title>Malek et al. - 1994 - Maternal-Fetal Transport of Immunoglobulin G and I.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://journals.lww.com/00000434-201104000-00002">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0002-9270"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Arsenescu</foaf:surname>
                        <foaf:givenName>Razvan</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Arsenescu</foaf:surname>
                        <foaf:givenName>Violeta</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>de Villiers</foaf:surname>
                        <foaf:givenName>Willem J S</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1512"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Animals, Newborn</dc:subject>
        <dc:subject>Antibodies</dc:subject>
        <dc:subject>Antibodies, Monoclonal</dc:subject>
        <dc:subject>Embryo, Mammalian</dc:subject>
        <dc:subject>Embryonic Development</dc:subject>
        <dc:subject>Immune System</dc:subject>
        <dc:subject>Mice</dc:subject>
        <dc:subject>Primates</dc:subject>
        <dc:subject>Tumor Necrosis Factor-alpha</dc:subject>
        <dc:title>TNF-α and the Development of the Neonatal Immune System: Implications for Inhibitor Use in Pregnancy</dc:title>
        <dc:date>04/2011</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>TNF-α and the Development of the Neonatal Immune System</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.lww.com/00000434-201104000-00002</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:27</dcterms:dateSubmitted>
        <dc:description>PMID: 21468063</dc:description>
        <bib:pages>559-562</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0002-9270">
        <prism:volume>106</prism:volume>
        <dc:title>American Journal of Gastroenterology</dc:title>
        <dc:identifier>DOI 10.1038/ajg.2011.5</dc:identifier>
        <prism:number>4</prism:number>
        <dc:identifier>ISSN 0002-9270</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1512">
        <z:itemType>attachment</z:itemType>
        <dc:title>Arsenescu et al. - 2011 - TNF-α and the Development of the Neonatal Immune S.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04079-2020">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:0903-1936,%201399-3003"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Baughman</foaf:surname>
                        <foaf:givenName>Robert P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Valeyre</foaf:surname>
                        <foaf:givenName>Dominique</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Korsten</foaf:surname>
                        <foaf:givenName>Peter</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Mathioudakis</foaf:surname>
                        <foaf:givenName>Alexander G.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wuyts</foaf:surname>
                        <foaf:givenName>Wim A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Wells</foaf:surname>
                        <foaf:givenName>Athol</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rottoli</foaf:surname>
                        <foaf:givenName>Paola</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nunes</foaf:surname>
                        <foaf:givenName>Hiliaro</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lower</foaf:surname>
                        <foaf:givenName>Elyse E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Judson</foaf:surname>
                        <foaf:givenName>Marc A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Israel-Biet</foaf:surname>
                        <foaf:givenName>Dominique</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Grutters</foaf:surname>
                        <foaf:givenName>Jan C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Drent</foaf:surname>
                        <foaf:givenName>Marjolein</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Culver</foaf:surname>
                        <foaf:givenName>Daniel A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bonella</foaf:surname>
                        <foaf:givenName>Francesco</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Antoniou</foaf:surname>
                        <foaf:givenName>Katerina</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Martone</foaf:surname>
                        <foaf:givenName>Filippo</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Quadder</foaf:surname>
                        <foaf:givenName>Bernd</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Spitzer</foaf:surname>
                        <foaf:givenName>Ginger</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Nagavci</foaf:surname>
                        <foaf:givenName>Blin</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Tonia</foaf:surname>
                        <foaf:givenName>Thomy</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Rigau</foaf:surname>
                        <foaf:givenName>David</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Ouellette</foaf:surname>
                        <foaf:givenName>Daniel R.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1513"/>
        <dc:title>ERS clinical practice guidelines on treatment of sarcoidosis</dc:title>
        <dcterms:abstract>Background: The major reasons to treat sarcoidosis are to lower the morbidity and mortality risk or to improve quality of life (QoL). The indication for treatment varies depending on which manifestation is the cause of symptoms: lungs, heart, brain, skin, or other manifestations. While glucocorticoids (GC) remain the first choice for initial treatment of symptomatic disease, prolonged use is associated with significant toxicity. GC-sparing alternatives are available. The presented treatment guideline aims to provide guidance to physicians treating the very heterogenous sarcoidosis manifestations. Materials and methods A European Respiratory Society Task Force (TF) committee composed of clinicians, methodologists, and patients with experience in sarcoidosis developed recommendations based on the GRADE (Grading of Recommendations, Assessment, Development and Evaluations) methodology. The committee developed eight PICO (Patients, Intervention, Comparison, Outcomes) questions and these were used to make specific evidence-based recommendations.
Results The TF committee delivered twelve recommendations for seven PICOs. These included treatment of pulmonary, cutaneous, cardiac, and neurologic disease as well as fatigue. One PICO question regarding small fiber neuropathy had insufficient evidence to support a recommendation. In addition to the recommendations, the committee provided information on how they use alternative treatments, when there was insufficient evidence to support a recommendation.
Conclusions There are many treatments available to treat sarcoidosis. Given the diverse nature of the disease, treatment decisions require an assessment of organ involvement, risk for significant morbidity, and impact on QoL of the disease and treatment.</dcterms:abstract>
        <dc:date>12/2021</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>http://erj.ersjournals.com/lookup/doi/10.1183/13993003.04079-2020</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:29</dcterms:dateSubmitted>
        <dc:description>PMID: 34140301</dc:description>
        <bib:pages>2004079</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:0903-1936,%201399-3003">
        <prism:volume>58</prism:volume>
        <dc:title>European Respiratory Journal</dc:title>
        <dc:identifier>DOI 10.1183/13993003.04079-2020</dc:identifier>
        <prism:number>6</prism:number>
        <dcterms:alternative>Eur Respir J</dcterms:alternative>
        <dc:identifier>ISSN 0903-1936, 1399-3003</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1513">
        <z:itemType>attachment</z:itemType>
        <dc:title>Baughman et al. - 2021 - ERS clinical practice guidelines on treatment of s.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://onlinelibrary.wiley.com/doi/10.1002/bdrb.10035">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1542-9733,%201542-9741"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Holsapple</foaf:surname>
                        <foaf:givenName>Michael P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>West</foaf:surname>
                        <foaf:givenName>Lori J.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Landreth</foaf:surname>
                        <foaf:givenName>Kenneth S.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1514"/>
        <dc:subject>Age Distribution</dc:subject>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Animals, Newborn</dc:subject>
        <dc:subject>Disease Models, Animal</dc:subject>
        <dc:subject>Dogs</dc:subject>
        <dc:subject>Humans</dc:subject>
        <dc:subject>Immune System</dc:subject>
        <dc:subject>Infant, Newborn</dc:subject>
        <dc:subject>Mice</dc:subject>
        <dc:subject>Models, Anatomic</dc:subject>
        <dc:subject>Models, Biological</dc:subject>
        <dc:subject>Species Specificity</dc:subject>
        <dc:title>Species comparison of anatomical and functional immune system development</dc:title>
        <dc:date>08/2003</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://onlinelibrary.wiley.com/doi/10.1002/bdrb.10035</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:31</dcterms:dateSubmitted>
        <dc:description>PMID: 14666995</dc:description>
        <bib:pages>321-334</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1542-9733,%201542-9741">
        <prism:volume>68</prism:volume>
        <dc:title>Birth Defects Research Part B: Developmental and Reproductive Toxicology</dc:title>
        <dc:identifier>DOI 10.1002/bdrb.10035</dc:identifier>
        <prism:number>4</prism:number>
        <dcterms:alternative>Birth Defect Res B</dcterms:alternative>
        <dc:identifier>ISSN 1542-9733, 1542-9741</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1514">
        <z:itemType>attachment</z:itemType>
        <dc:title>Holsapple et al. - 2003 - Species comparison of anatomical and functional im.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://journals.lww.com/00063198-201609000-00015">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1070-5287"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Bonham</foaf:surname>
                        <foaf:givenName>Catherine A.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Strek</foaf:surname>
                        <foaf:givenName>Mary E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Patterson</foaf:surname>
                        <foaf:givenName>Karen C.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1515"/>
        <dc:title>From granuloma to fibrosis: sarcoidosis associated pulmonary fibrosis</dc:title>
        <dcterms:abstract>Purpose of review—Up to twenty percent of patients with sarcoidosis develop pulmonary fibrosis, transforming an often benign disease into a highly morbid and potentially fatal one. We highlight the fibrotic pulmonary sarcoidosis phenotype as an area of intense clinical and translational investigation, review recent developments in treatment, and provide a roadmap for future research in sarcoidosis associated pulmonary fibrosis.</dcterms:abstract>
        <dc:date>09/2016</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>From granuloma to fibrosis</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://journals.lww.com/00063198-201609000-00015</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:33</dcterms:dateSubmitted>
        <dc:description>PMID: 27379967
PMCID: PMC5532138</dc:description>
        <bib:pages>484-491</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1070-5287">
        <prism:volume>22</prism:volume>
        <dc:title>Current Opinion in Pulmonary Medicine</dc:title>
        <dc:identifier>DOI 10.1097/MCP.0000000000000301</dc:identifier>
        <prism:number>5</prism:number>
        <dc:identifier>ISSN 1070-5287</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1515">
        <z:itemType>attachment</z:itemType>
        <dc:title>Bonham et al. - 2016 - From granuloma to fibrosis sarcoidosis associated.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.dovepress.com/tumor-necrosis-factor-alpha-inhibitor-treatment-for-sarcoidosis-peer-reviewed-article-TCRM">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:1178-203X"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Callejas-Rubio</foaf:surname>
                        <foaf:givenName>Jose</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1516"/>
        <dc:subject>adalimumab</dc:subject>
        <dc:subject>anti-TNA alpha</dc:subject>
        <dc:subject>etanercept</dc:subject>
        <dc:subject>infliximab</dc:subject>
        <dc:subject>sarcoidosis</dc:subject>
        <dc:title>Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis</dc:title>
        <dcterms:abstract>Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by noncaseating granulomatous inﬁltration of virtually any organ system. Treatment is often undertaken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies have suggested a prominent role for tumor necrosis factor-alpha (TNF-α) in the inﬂammatory process seen in sarcoidosis. TNF-α and interleukin-1 are released by alveolar macrophages in patients with active lung disease. Corticosteroids have proved to be efﬁcacious in the treatment of sarcoidosis, possibly by suppressing the production of TNF-α and other cytokines. Three agents are currently available as speciﬁc TNF antagonists: etanercept, inﬂiximab, and adalimumab. Although data from noncomparative trials suggest that all three have comparable therapeutic effects in rheumatoid arthritis, their effects in a granulomatous disease such as sarcoidosis are less consistent. In this review, current data on the effectiveness are summarized.</dcterms:abstract>
        <dc:date>12/2008</dc:date>
        <z:language>en</z:language>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.dovepress.com/tumor-necrosis-factor-alpha-inhibitor-treatment-for-sarcoidosis-peer-reviewed-article-TCRM</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:35</dcterms:dateSubmitted>
        <dc:description>PMID: 19337437</dc:description>
        <bib:pages>1305-1313</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:1178-203X">
        <prism:volume>Volume 4</prism:volume>
        <dc:title>Therapeutics and Clinical Risk Management</dc:title>
        <dc:identifier>DOI 10.2147/TCRM.S967</dc:identifier>
        <dcterms:alternative>TCRM</dcterms:alternative>
        <dc:identifier>ISSN 1178-203X</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1516">
        <z:itemType>attachment</z:itemType>
        <dc:title>Callejas-Rubio - 2008 - Tumor necrosis factor-alpha inhibitor treatment fo.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
    <bib:Article rdf:about="https://www.nature.com/articles/s41598-020-63465-y">
        <z:itemType>journalArticle</z:itemType>
        <dcterms:isPartOf rdf:resource="urn:issn:2045-2322"/>
        <bib:authors>
            <rdf:Seq>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Lazic</foaf:surname>
                        <foaf:givenName>Stanley E.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Semenova</foaf:surname>
                        <foaf:givenName>Elizaveta</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
                <rdf:li>
                    <foaf:Person>
                        <foaf:surname>Williams</foaf:surname>
                        <foaf:givenName>Dominic P.</foaf:givenName>
                    </foaf:Person>
                </rdf:li>
            </rdf:Seq>
        </bib:authors>
        <link:link rdf:resource="#item_1517"/>
        <dc:subject>Animals</dc:subject>
        <dc:subject>Bayes Theorem</dc:subject>
        <dc:subject>Body Weight</dc:subject>
        <dc:subject>Chromates</dc:subject>
        <dc:subject>Computer Simulation</dc:subject>
        <dc:subject>Female</dc:subject>
        <dc:subject>Liver</dc:subject>
        <dc:subject>Models, Biological</dc:subject>
        <dc:subject>Organ Size</dc:subject>
        <dc:subject>Probability</dc:subject>
        <dc:subject>Rats, Inbred F344</dc:subject>
        <dc:subject>Toxicity Tests</dc:subject>
        <dc:title>Determining organ weight toxicity with Bayesian causal models: Improving on the analysis of relative organ weights</dc:title>
        <dcterms:abstract>Abstract
            Regulatory authorities require animal toxicity tests for new chemical entities. Organ weight changes are accepted as a sensitive indicator of chemically induced organ damage, but can be difficult to interpret because changes in organ weight might reflect chemically-induced changes in overall body weight. A common solution is to calculate the relative organ weight (organ to body weight ratio), but this inadequately controls for the dependence on body weight – a point made by statisticians for decades, but which has not been widely adopted. The recommended solution is an analysis of covariance (ANCOVA), but it is rarely used, possibly because both the method of statistical correction and the interpretation of the output may be unclear to those with minimal statistical training. Using relative organ weights can easily lead to incorrect conclusions, resulting in poor decisions, wasted resources, and an ethically questionable use of animals. We propose to cast the problem into a causal modelling framework as it directly assesses questions of scientific interest, the results are easy to interpret, and the analysis is simple to perform with freely available software. Furthermore, by taking a Bayesian approach we can model unequal variances, control for multiple testing, and directly provide evidence of safety.</dcterms:abstract>
        <dc:date>2020-04-20</dc:date>
        <z:language>en</z:language>
        <z:shortTitle>Determining organ weight toxicity with Bayesian causal models</z:shortTitle>
        <z:libraryCatalog>DOI.org (Crossref)</z:libraryCatalog>
        <dc:identifier>
            <dcterms:URI>
                <rdf:value>https://www.nature.com/articles/s41598-020-63465-y</rdf:value>
            </dcterms:URI>
        </dc:identifier>
        <dcterms:dateSubmitted>2023-04-11 22:03:37</dcterms:dateSubmitted>
        <dc:description>PMID: 32313041
PMCID: PMC7170916</dc:description>
        <bib:pages>6625</bib:pages>
    </bib:Article>
    <bib:Journal rdf:about="urn:issn:2045-2322">
        <prism:volume>10</prism:volume>
        <dc:title>Scientific Reports</dc:title>
        <dc:identifier>DOI 10.1038/s41598-020-63465-y</dc:identifier>
        <prism:number>1</prism:number>
        <dcterms:alternative>Sci Rep</dcterms:alternative>
        <dc:identifier>ISSN 2045-2322</dc:identifier>
    </bib:Journal>
    <z:Attachment rdf:about="#item_1517">
        <z:itemType>attachment</z:itemType>
        <dc:title>Lazic et al. - 2020 - Determining organ weight toxicity with Bayesian ca.pdf</dc:title>
        <link:type>application/pdf</link:type>
    </z:Attachment>
</rdf:RDF>
